Stiff-Person Syndrome (SPS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 

Stiff person syndrome (SPS) encompasses a spectrum of disorders characterized by progressively increasing axial rigidity accompanied by intermittent, painful spasms. This condition predominantly affects females and may arise idiopathically or secondary to autoimmune disorders or paraneoplastic conditions, accounting for approximately 5% of cases. Variants within this syndrome include stiff limb syndrome, jerking stiff person syndrome, and progressive encephalomyelitis with rigidity and myoclonus (PERM). The clinical course of SPS is variable, often ameliorating during sleep but exacerbating with movement, sensory stimuli, or emotional stress. Patients may also experience spasms and myoclonic jerks. In SPS, anti-glutamic acid decarboxylase (anti-GAD) autoantibodies are detected in 50–90% of cases, with other associated autoantibodies, including anti-amphiphysin and anti-glycine receptors. The presence of anti-GAD antibodies is predominantly linked to autoimmune diseases such as type 1 diabetes mellitus. In contrast, anti-amphiphysin and anti-glycine receptor antibodies are frequently associated with solid tumors. Paraneoplastic SPS often involves both limbs and may be accompanied by sensory neuronopathy. Notably, anti-glycine receptor antibodies can yield false positives outside the phenotypic spectrum of SPS and PERM, as seen in conditions like optic neuritis and epilepsy. Anti-amphiphysin antibodies may also be present in PERM, marked by altered consciousness, brainstem manifestations, myoclonus, cerebellar ataxia, and diffuse rigidity. Treatment for SPS is categorized into symptomatic management and disease-modifying or immunotherapeutic approaches. Typically, these therapeutic strategies are employed in combination based on disease severity. Symptomatic treatment, the cornerstone of initial therapy, aims to reduce stiffness, rigidity, and painful muscle spasms through agents that enhance GABAergic activity, including benzodiazepines, baclofen, gabapentin, and vigabatrin. Diazepam is frequently the first-line symptomatic agent for SPS, though tolerance and dependency on benzodiazepines may develop, diminishing their effectiveness over time. Intrathecal baclofen has shown efficacy in certain patients, while other muscle relaxants such as dantrolene and tizanidine are also utilized. Additionally, the management of coexisting seizures and psychiatric comorbidities involves the use of antiepileptic and antidepressant medications, respectively. Disease-modifying therapy involves immune modulation to reduce or eliminate autoantibodies. Intravenous immunoglobulin (IVIG) has demonstrated significant efficacy as an immunotherapy for SPS, providing clinical improvement for up to one year following a standard course of five sessions.

Thelansis’s “Stiff-Person Syndrome (SPS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Stiff-Person Syndrome (SPS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Stiff-Person Syndrome (SPS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Stiff-Person Syndrome (SPS) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Stiff-Person Syndrome (SPS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033